CombinatoRx, Incorporated - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of "CombinatoRx, Incorporated". The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.

CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company engaged in developing synergistic combinations pharmaceuticals. The company currently has a portfolio of six products in the 2nd phase clinical trials associated with the treatment of rheumatoid arthritis, psoriasis, atopic dermatitis, Type-2 diabetes and asthma. The company is headquartered in Cambridge, the US. On July 1, 2009, CombinatoRx, Incorporated entered into a definitive merger agreement with Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, under which CombinatoRx and Neuromed will merge in an all-stock transaction.

And More inside the report…

Recent Developments

Feb 16, 2010: CombinatoRx Announces Extension Of PDUFA Date For Exalgo Extended-Release Tablets
Jan 06, 2010: CombinatoRx Announces Senior Management Changes
Aug 12, 2009: Clinical Data Signs Collaboration, Licensing Agreement With CombinatoRx

Scope

- Provides key company information for business intelligence needs
- The company’s strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
- The opportunities open to the company are considered and its growth potential assessed. Competitive and/or technological threats are highlighted.
- The report contains critical company information – business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
- The report provides detailed financial ratios for the past five years as well as interim ratios for the last fourinterim periods.
- Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Reasons to buy

- A quick "one-stop-shop" to understand the company.
- Enhance business/sales activities by understanding customers’ businesses better.
- Get detailed information and financial & strategic analysis on companies operating in your industry.
- Identify prospective partners and suppliers – with key data on their businesses and locations.
- Capitalize on competitors’ weaknesses and target the market opportunities available to them.
- Compare your company’s financial trends with those of your peers / competitors.
- Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.